TruScreen Limited has provided a copy of its January 2018 Newsletter. This Newsletter is also available for viewing on the company website http://truscreen.com/investor-centre/reports-presentations/.
For more information visit www.truscreen.com or contact:
TruScreen Chief Executive Officer
Phone: +64 27 246 2505
TruScreen’s real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection.